Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to the launch of new products, which have enhanced sales growth and widened profit margins.
The latest trading day saw Boston Scientific (BSX) settling at $99.74, representing a +1.2% change from its previous close.
Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.
22 Jul 2025 (35 Days) Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
24 Oct 2024 Date | | - Cons. EPS | - EPS |
23 Oct 2024 Date | | - Cons. EPS | - EPS |
22 Jul 2025 (35 Days) Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
24 Oct 2024 Date | | - Cons. EPS | - EPS |
23 Oct 2024 Date | | - Cons. EPS | - EPS |
XFRA Exchange | US Country |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.